GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis

GLP-1/GLP-1R 信号在脂肪细胞分化和脂肪生成中的调节作用

阅读:4
作者:Jicui Chen, Huichen Zhao, Xiaoli Ma, Yuchao Zhang, Sumei Lu, Yangang Wang, Chen Zong, Dandan Qin, Yuanmei Wang, Yingfeng Yingfeng Yang, Xiangdong Wang, Yuantao Liu

Aims

The aim of this study was to determine the direct role of liraglutide (LG) in adipogenesis and lipid metabolism.

Background/aims

The aim of this study was to determine the direct role of liraglutide (LG) in adipogenesis and lipid metabolism.

Conclusion

LG promotes preadipocytes differentiation, and inhibits FASN expression in adipocytes. LG induced down-regulation of FASN is at least partially mediated by PKA and MAPK signaling pathways.

Methods

Lipid accumulation was evaluated by oil red O staining, quantitative real-time PCR (qPCR) was performed to determine glucagon-like peptide 1 receptor (GLP-1R), fatty acid synthase (FASN) and adipose triglyceride lipase (ATGL) expression in 3T3-L1 preadipocytes, differentiated adipocytes and in adipose tissues from mice. The effects of LG on 3T3-L1 adipogenesis and lipid metabolism were analyzed with qPCR, Western Blotting, oil red O staining, immunohistochemistry (IHC) and immunofluorescence (IF). All measurements were performed at least three times.

Results

LG increased the expression of differentiation marker genes and lipid accumulation during preadipocyte differentiation. In differentiated adipocytes, LG decreased FASN expression, and simultaneously led to CREB phosphorylation and ERK1/2 activation which were abolished by a GLP-1R antagonist, exendin (9-39). LG induced-FASN down-regulation was partially reversed by PKA and ERK1/2 inhibitors. Consistent with above in vitro findings, LG treatment significantly reduced FASN expression in visceral adipose tissues of ob/ob mice, and reduced body weight gain.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。